Concepts (171)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
HIV Infections | 32 | 2024 | 17352 | 0.730 |
Why?
|
Antiretroviral Therapy, Highly Active | 12 | 2024 | 1897 | 0.680 |
Why?
|
Anti-HIV Agents | 18 | 2024 | 4527 | 0.670 |
Why?
|
Anti-Retroviral Agents | 6 | 2022 | 1784 | 0.620 |
Why?
|
Epidemiologic Research Design | 1 | 2019 | 368 | 0.530 |
Why?
|
Zambia | 16 | 2012 | 262 | 0.490 |
Why?
|
Statistics as Topic | 1 | 2020 | 2358 | 0.460 |
Why?
|
Biostatistics | 1 | 2015 | 164 | 0.430 |
Why?
|
Epidemiologic Methods | 2 | 2015 | 1336 | 0.360 |
Why?
|
Hemoglobins | 2 | 2012 | 1526 | 0.280 |
Why?
|
RNA, Viral | 6 | 2023 | 2846 | 0.270 |
Why?
|
Pregnancy Complications, Infectious | 6 | 2024 | 2151 | 0.270 |
Why?
|
Infectious Disease Transmission, Vertical | 5 | 2013 | 1351 | 0.250 |
Why?
|
Viral Load | 4 | 2024 | 3332 | 0.240 |
Why?
|
Zidovudine | 3 | 2024 | 624 | 0.220 |
Why?
|
Anemia | 1 | 2012 | 1509 | 0.210 |
Why?
|
Latin America | 4 | 2017 | 410 | 0.200 |
Why?
|
CD4 Lymphocyte Count | 9 | 2017 | 2571 | 0.200 |
Why?
|
Antibodies, Viral | 4 | 2024 | 3156 | 0.180 |
Why?
|
Nevirapine | 2 | 2010 | 273 | 0.160 |
Why?
|
Adult | 36 | 2024 | 221203 | 0.150 |
Why?
|
Observation | 1 | 2019 | 310 | 0.150 |
Why?
|
Caribbean Region | 2 | 2015 | 191 | 0.150 |
Why?
|
Stillbirth | 2 | 2011 | 368 | 0.150 |
Why?
|
Public Health | 1 | 2010 | 2669 | 0.140 |
Why?
|
Hospitalization | 3 | 2024 | 10721 | 0.130 |
Why?
|
Adenine | 2 | 2011 | 987 | 0.120 |
Why?
|
Antibodies, Monoclonal | 4 | 2024 | 9177 | 0.120 |
Why?
|
Antiviral Agents | 5 | 2024 | 3060 | 0.120 |
Why?
|
Cohort Studies | 11 | 2020 | 41493 | 0.120 |
Why?
|
HIV-1 | 5 | 2017 | 6863 | 0.110 |
Why?
|
Malnutrition | 2 | 2010 | 645 | 0.110 |
Why?
|
Humans | 48 | 2024 | 761572 | 0.110 |
Why?
|
Premature Birth | 1 | 2024 | 1782 | 0.100 |
Why?
|
Female | 37 | 2024 | 392686 | 0.100 |
Why?
|
Pregnancy | 12 | 2024 | 29876 | 0.090 |
Why?
|
Developing Countries | 2 | 2013 | 2885 | 0.090 |
Why?
|
Continuity of Patient Care | 1 | 2017 | 1069 | 0.090 |
Why?
|
Infant Mortality | 2 | 2013 | 759 | 0.080 |
Why?
|
Male | 27 | 2024 | 360842 | 0.080 |
Why?
|
Fetal Death | 1 | 2011 | 435 | 0.080 |
Why?
|
Acquired Immunodeficiency Syndrome | 1 | 2018 | 2199 | 0.080 |
Why?
|
Contraceptives, Oral, Hormonal | 1 | 2009 | 190 | 0.080 |
Why?
|
Safety | 1 | 2012 | 1150 | 0.070 |
Why?
|
Child Health Services | 1 | 2013 | 646 | 0.070 |
Why?
|
Treatment Outcome | 11 | 2024 | 64684 | 0.070 |
Why?
|
Young Adult | 10 | 2024 | 59255 | 0.070 |
Why?
|
Prenatal Care | 2 | 2011 | 1139 | 0.070 |
Why?
|
Software | 1 | 2020 | 4434 | 0.070 |
Why?
|
Health Knowledge, Attitudes, Practice | 2 | 2012 | 4016 | 0.070 |
Why?
|
Health Education | 1 | 2012 | 1052 | 0.060 |
Why?
|
Africa | 3 | 2013 | 709 | 0.060 |
Why?
|
Proportional Hazards Models | 6 | 2016 | 12463 | 0.060 |
Why?
|
Age Distribution | 1 | 2010 | 2880 | 0.060 |
Why?
|
Inflammation | 1 | 2024 | 10773 | 0.060 |
Why?
|
Antibodies, Neutralizing | 2 | 2024 | 1943 | 0.060 |
Why?
|
Adolescent | 9 | 2017 | 88324 | 0.050 |
Why?
|
Middle Aged | 13 | 2024 | 220920 | 0.050 |
Why?
|
RNA | 2 | 2023 | 2726 | 0.050 |
Why?
|
Infant, Newborn | 6 | 2013 | 26198 | 0.050 |
Why?
|
Survival Analysis | 2 | 2012 | 10090 | 0.050 |
Why?
|
Half-Life | 1 | 2023 | 651 | 0.050 |
Why?
|
Child, Preschool | 6 | 2022 | 42230 | 0.050 |
Why?
|
Urban Population | 1 | 2010 | 2036 | 0.050 |
Why?
|
Respiratory Tract Infections | 1 | 2009 | 1010 | 0.050 |
Why?
|
Data Collection | 1 | 2010 | 3322 | 0.050 |
Why?
|
Honduras | 1 | 2020 | 37 | 0.040 |
Why?
|
Biological Assay | 1 | 2023 | 626 | 0.040 |
Why?
|
Rural Population | 1 | 2011 | 2285 | 0.040 |
Why?
|
Cause of Death | 1 | 2011 | 3683 | 0.040 |
Why?
|
Pregnancy Outcome | 1 | 2011 | 2922 | 0.040 |
Why?
|
Infant | 6 | 2013 | 36192 | 0.040 |
Why?
|
Weight Gain | 1 | 2010 | 2348 | 0.040 |
Why?
|
Argentina | 1 | 2020 | 246 | 0.040 |
Why?
|
Chile | 1 | 2020 | 256 | 0.040 |
Why?
|
Models, Biological | 2 | 2013 | 9469 | 0.040 |
Why?
|
Drug Therapy, Combination | 2 | 2024 | 6312 | 0.040 |
Why?
|
Drug Resistance, Viral | 1 | 2024 | 862 | 0.040 |
Why?
|
Double-Blind Method | 2 | 2023 | 12341 | 0.040 |
Why?
|
Retrospective Studies | 10 | 2022 | 80646 | 0.040 |
Why?
|
Cross-Sectional Studies | 4 | 2017 | 26127 | 0.040 |
Why?
|
Drug Combinations | 1 | 2024 | 2048 | 0.040 |
Why?
|
Child | 7 | 2022 | 80156 | 0.040 |
Why?
|
Viremia | 1 | 2021 | 707 | 0.040 |
Why?
|
Urban Health | 2 | 2011 | 532 | 0.040 |
Why?
|
Mexico | 1 | 2020 | 764 | 0.040 |
Why?
|
CD4-Positive T-Lymphocytes | 1 | 2009 | 4369 | 0.030 |
Why?
|
Outpatients | 1 | 2024 | 1597 | 0.030 |
Why?
|
Pneumonia, Pneumocystis | 1 | 2018 | 242 | 0.030 |
Why?
|
Brazil | 1 | 2020 | 1230 | 0.030 |
Why?
|
Sex Characteristics | 1 | 2006 | 2639 | 0.030 |
Why?
|
South America | 1 | 2016 | 179 | 0.030 |
Why?
|
Kinetics | 1 | 2023 | 6374 | 0.030 |
Why?
|
Phosphoproteins | 1 | 2024 | 2448 | 0.030 |
Why?
|
Time Factors | 4 | 2023 | 39970 | 0.030 |
Why?
|
Aging | 2 | 2020 | 8711 | 0.030 |
Why?
|
Aged | 5 | 2024 | 169310 | 0.030 |
Why?
|
Program Evaluation | 2 | 2013 | 2495 | 0.030 |
Why?
|
Electronic Health Records | 1 | 2011 | 4811 | 0.030 |
Why?
|
Primary Health Care | 1 | 2010 | 4686 | 0.030 |
Why?
|
Age Factors | 3 | 2018 | 18398 | 0.030 |
Why?
|
Grenada | 1 | 2012 | 3 | 0.030 |
Why?
|
Drowning | 1 | 2012 | 26 | 0.030 |
Why?
|
Disease Progression | 1 | 2009 | 13510 | 0.030 |
Why?
|
North America | 1 | 2016 | 1276 | 0.030 |
Why?
|
Gestational Age | 2 | 2011 | 3577 | 0.030 |
Why?
|
Algorithms | 1 | 2013 | 14032 | 0.030 |
Why?
|
Predictive Value of Tests | 3 | 2013 | 15266 | 0.020 |
Why?
|
Liver Diseases | 1 | 2020 | 1298 | 0.020 |
Why?
|
Immunoglobulin G | 1 | 2023 | 4544 | 0.020 |
Why?
|
Canada | 1 | 2016 | 2122 | 0.020 |
Why?
|
Lymphoma, Non-Hodgkin | 1 | 2018 | 1374 | 0.020 |
Why?
|
Faculty | 1 | 2012 | 384 | 0.020 |
Why?
|
Area Under Curve | 1 | 2013 | 1638 | 0.020 |
Why?
|
Multivariate Analysis | 2 | 2013 | 12059 | 0.020 |
Why?
|
Perinatal Care | 1 | 2011 | 243 | 0.020 |
Why?
|
Syphilis | 1 | 2011 | 243 | 0.020 |
Why?
|
Family Characteristics | 1 | 2013 | 1004 | 0.020 |
Why?
|
Asia | 1 | 2009 | 619 | 0.020 |
Why?
|
Early Diagnosis | 1 | 2013 | 1186 | 0.020 |
Why?
|
Maternal Health Services | 1 | 2013 | 461 | 0.020 |
Why?
|
Follow-Up Studies | 2 | 2022 | 39107 | 0.020 |
Why?
|
Autopsy | 1 | 2011 | 1009 | 0.020 |
Why?
|
Primates | 1 | 2009 | 523 | 0.020 |
Why?
|
Risk Factors | 5 | 2013 | 74213 | 0.020 |
Why?
|
Reverse Transcriptase Inhibitors | 1 | 2010 | 621 | 0.020 |
Why?
|
Drugs, Generic | 1 | 2012 | 448 | 0.020 |
Why?
|
Odds Ratio | 2 | 2011 | 9646 | 0.020 |
Why?
|
Logistic Models | 2 | 2011 | 13255 | 0.020 |
Why?
|
DNA, Viral | 1 | 2013 | 2202 | 0.020 |
Why?
|
Renal Insufficiency, Chronic | 1 | 2020 | 2243 | 0.020 |
Why?
|
Case-Control Studies | 1 | 2024 | 22176 | 0.020 |
Why?
|
Water | 1 | 2012 | 1411 | 0.020 |
Why?
|
HIV | 1 | 2013 | 1582 | 0.020 |
Why?
|
Health Care Surveys | 1 | 2013 | 2426 | 0.020 |
Why?
|
Health Status Indicators | 1 | 2011 | 970 | 0.020 |
Why?
|
Health Services Research | 1 | 2013 | 1812 | 0.020 |
Why?
|
Seroepidemiologic Studies | 1 | 2006 | 397 | 0.020 |
Why?
|
Tuberculosis | 1 | 2018 | 2017 | 0.010 |
Why?
|
Analysis of Variance | 1 | 2013 | 6228 | 0.010 |
Why?
|
Treatment Failure | 1 | 2010 | 2644 | 0.010 |
Why?
|
Medical Records | 1 | 2009 | 1408 | 0.010 |
Why?
|
Educational Status | 1 | 2011 | 2522 | 0.010 |
Why?
|
Polymerase Chain Reaction | 1 | 2013 | 6075 | 0.010 |
Why?
|
Schools | 1 | 2012 | 1489 | 0.010 |
Why?
|
Fetal Blood | 1 | 2010 | 1347 | 0.010 |
Why?
|
Prevalence | 1 | 2020 | 15732 | 0.010 |
Why?
|
Quality Indicators, Health Care | 1 | 2013 | 1792 | 0.010 |
Why?
|
Birth Weight | 1 | 2011 | 2103 | 0.010 |
Why?
|
Disease-Free Survival | 1 | 2013 | 6815 | 0.010 |
Why?
|
Mothers | 1 | 2013 | 2198 | 0.010 |
Why?
|
Drug Administration Schedule | 1 | 2010 | 4853 | 0.010 |
Why?
|
Regression Analysis | 1 | 2011 | 6344 | 0.010 |
Why?
|
Diabetes Mellitus | 1 | 2020 | 5841 | 0.010 |
Why?
|
Mental Disorders | 1 | 2020 | 6845 | 0.010 |
Why?
|
Feasibility Studies | 1 | 2011 | 5247 | 0.010 |
Why?
|
India | 1 | 2006 | 2348 | 0.010 |
Why?
|
Population Surveillance | 1 | 2010 | 2598 | 0.010 |
Why?
|
Cost-Benefit Analysis | 1 | 2012 | 5492 | 0.010 |
Why?
|
Socioeconomic Factors | 1 | 2013 | 7827 | 0.010 |
Why?
|
Research Design | 1 | 2013 | 6180 | 0.010 |
Why?
|
Health Services Accessibility | 1 | 2013 | 5440 | 0.010 |
Why?
|
Mass Screening | 1 | 2011 | 5428 | 0.010 |
Why?
|
Delivery of Health Care | 1 | 2012 | 5336 | 0.010 |
Why?
|
Reproducibility of Results | 1 | 2013 | 20099 | 0.010 |
Why?
|
Cardiovascular Diseases | 1 | 2020 | 15501 | 0.010 |
Why?
|
Body Mass Index | 1 | 2010 | 12954 | 0.010 |
Why?
|
Prognosis | 1 | 2013 | 29629 | 0.010 |
Why?
|
Neoplasms | 1 | 2020 | 22173 | 0.010 |
Why?
|
United States | 1 | 2016 | 72335 | 0.000 |
Why?
|
Animals | 1 | 2009 | 168467 | 0.000 |
Why?
|
Concepts
(171)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(10)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People in same department with this person.
Explore
_